Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hideaki Bando

Showing results (151-160 of 186) with videos related to

Pageof 19
Sort By:
British Journal of Cancer|October 4, 2017
Clinical significance of BRAF non-V600E mutations on the therapeutic effects of anti-EGFR monoclonal antibody treatment in patients with pretreated metastatic colorectal cancer: the Biomarker Research for anti-EGFR monoclonal Antibodies by Comprehensive Cancer genomics (BREAC) studyEiji Shinozaki, Takayuki Yoshino, Kentaro Yamazaki, et al.
International Journal of Clinical Oncology|March 1, 2023
Regulation of MEK inhibitor selumetinib sensitivity by AKT phosphorylation in the novel BRAF L525R mutantChikako Nakai, Sachiyo Mimaki, Koutatsu Matsushima, et al.
British Journal of Cancer|August 28, 2024
Clinical utility of BRCA and ATM mutation status in circulating tumour DNA for treatment selection in advanced pancreatic cancerKentaro Sudo, Yoshiaki Nakamura, Makoto Ueno, et al.
Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association|November 2, 2024
Prognostic and predictive factors for the efficacy and safety of trastuzumab deruxtecan in HER2-positive gastric or gastroesophageal junction cancerAmane Jubashi, Izuma Nakayama, Shigehiro Koganemaru, et al.
Biomedical Reports|October 1, 2019
Histopathological factors affecting the extraction of high quality genomic DNA from tissue sections for next-generation sequencingSatoshi Fujii, Takayuki Yoshino, Kentaro Yamazaki, et al.
International Journal of Clinical Oncology|May 23, 2026
SCRUM-Japan MONSTAR3 hematology cohort: a nationwide multi-omics integrated platform for next-generation precision medicine in hematologic malignanciesKensuke Matsuda, Junichiro Yuda, Ryo Yoshimaru, et al.
British Journal of Cancer|February 13, 2023
Clinical significance of circulating-tumour DNA analysis by metastatic sites in pancreatic cancerKumiko Umemoto, Yu Sunakawa, Makoto Ueno, et al.
Annals of Surgery|March 21, 2025
Circulating Tumor DNA Assessment to Predict Risk of Recurrence after Surgery in Patients with Locally Advanced Esophageal Squamous Cell Carcinoma: A Prospective Observational StudyShogo Takei, Daisuke Kotani, George Laliotis, et al.
JCO Precision Oncology|May 11, 2022
Effects of Metastatic Sites on Circulating Tumor DNA in Patients With Metastatic Colorectal CancerHideaki Bando, Yoshiaki Nakamura, Hiroya Taniguchi, et al.
JCO Oncology Practice|December 19, 2025
Durable Complete Response and Potential Cure With Systemic Chemotherapy in Metastatic Gastric Cancer: A Case Series of PatientsShinpei Ushiyama, Takumi Habu, Izuma Nakayama, et al.
Pageof 19

Showing results (151-160 of 186) with videos related to

Sort By:
Pageof 19
British Journal of Cancer|October 4, 2017
Clinical significance of BRAF non-V600E mutations on the therapeutic effects of anti-EGFR monoclonal antibody treatment in patients with pretreated metastatic colorectal cancer: the Biomarker Research for anti-EGFR monoclonal Antibodies by Comprehensive Cancer genomics (BREAC) studyEiji Shinozaki, Takayuki Yoshino, Kentaro Yamazaki, et al.
International Journal of Clinical Oncology|March 1, 2023
Regulation of MEK inhibitor selumetinib sensitivity by AKT phosphorylation in the novel BRAF L525R mutantChikako Nakai, Sachiyo Mimaki, Koutatsu Matsushima, et al.
British Journal of Cancer|August 28, 2024
Clinical utility of BRCA and ATM mutation status in circulating tumour DNA for treatment selection in advanced pancreatic cancerKentaro Sudo, Yoshiaki Nakamura, Makoto Ueno, et al.
Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association|November 2, 2024
Prognostic and predictive factors for the efficacy and safety of trastuzumab deruxtecan in HER2-positive gastric or gastroesophageal junction cancerAmane Jubashi, Izuma Nakayama, Shigehiro Koganemaru, et al.
Biomedical Reports|October 1, 2019
Histopathological factors affecting the extraction of high quality genomic DNA from tissue sections for next-generation sequencingSatoshi Fujii, Takayuki Yoshino, Kentaro Yamazaki, et al.
International Journal of Clinical Oncology|May 23, 2026
SCRUM-Japan MONSTAR3 hematology cohort: a nationwide multi-omics integrated platform for next-generation precision medicine in hematologic malignanciesKensuke Matsuda, Junichiro Yuda, Ryo Yoshimaru, et al.
British Journal of Cancer|February 13, 2023
Clinical significance of circulating-tumour DNA analysis by metastatic sites in pancreatic cancerKumiko Umemoto, Yu Sunakawa, Makoto Ueno, et al.
Annals of Surgery|March 21, 2025
Circulating Tumor DNA Assessment to Predict Risk of Recurrence after Surgery in Patients with Locally Advanced Esophageal Squamous Cell Carcinoma: A Prospective Observational StudyShogo Takei, Daisuke Kotani, George Laliotis, et al.
JCO Precision Oncology|May 11, 2022
Effects of Metastatic Sites on Circulating Tumor DNA in Patients With Metastatic Colorectal CancerHideaki Bando, Yoshiaki Nakamura, Hiroya Taniguchi, et al.
JCO Oncology Practice|December 19, 2025
Durable Complete Response and Potential Cure With Systemic Chemotherapy in Metastatic Gastric Cancer: A Case Series of PatientsShinpei Ushiyama, Takumi Habu, Izuma Nakayama, et al.
Pageof 19